Identification of clonally expanded γδ T-cell populations during CAR-T cell therapy
- PMID: 39500484
- DOI: 10.1111/imcb.12834
Identification of clonally expanded γδ T-cell populations during CAR-T cell therapy
Abstract
Anti-CD19 Chimeric Antigen Receptor (CAR)-T cell therapies have shown promise for treating B cell malignancies, but the clinical outcome is influenced by both the CAR-T product and the patient's immune system. The role of γδ T cells in the context of CAR-T cell therapy remains poorly understood. This study investigates the transcriptional heterogeneity, clonal expansion and dynamics of γδ T cells in patients undergoing anti-CD19 CAR-T cell therapy. Longitudinal single cell multi-omics analysis was performed on γδ T cells from four patients receiving anti-CD19 CAR-T cell therapy. Single cell RNA-seq, antibody-based protein profiling (AbSeq) and full-length TCRγδ sequences revealed clonally expanded populations displaying plasticity in T cell differentiation, and temporal dynamics of large clones, suggesting ongoing expansion and differentiation. Clonally expanded γδ T cells had heterogeneous gene expression profiles, occupying seven transcriptionally distinct clusters. Analysis of chemokine markers indicated cluster-specific homing tendencies of circulating γδ T cells to peripheral tissues. We found unexpectedly high frequencies of Vδ1 and Vδ3 cells in the blood with distinct gene and protein expression profiles. This analysis provides insights into the dynamic and heterogeneous nature of γδ T cells following anti-CD19 CAR-T cell therapy, contributing valuable information for optimizing CAR-T cell therapies in B cell malignancies.
Keywords: CAR‐T cells; T cell receptors; immune reconstitution; immune response dynamics; single cell RNA‐seq; γδ T cells.
© 2024 the Australian and New Zealand Society for Immunology, Inc.
References
REFERENCES
-
- Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature 2023; 614: 635–648.
-
- Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 2022; 19: 342–355.
-
- Louie RHY, Cai C, Samir J, et al. CAR+ and CAR− T cells share a differentiation trajectory into an NK‐like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat Commun 2023; 14: 7767.
-
- Good Z, Spiegel JY, Sahaf B, et al. Post‐infusion CAR TReg cells identify patients resistant to CD19‐CAR therapy. Nat Med 2022; 28: 1860–1871.
-
- Pizzolato G, Kaminski H, Tosolini M, et al. Single‐cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci USA 2019; 116: 11906–11915.
Publication types
MeSH terms
Substances
Grants and funding
- 1102172/National Health and Medical Research Council, Australia
- 1121704/National Health and Medical Research Council, Australia
- 1121643/National Health and Medical Research Council, Australia
- 1128416/National Health and Medical Research Council, Australia
- TPG 19-01/Cancer Council NSW and the Cancer Institute NSW
LinkOut - more resources
Full Text Sources